glp-1 kidney function The privileged position of in diabetic nephropathy Real-World Evidence for GLP-1 Receptor

Prolactin: None of the compounds affected prolactin at the doses tested in the original study, though subsequent work has shown that GHRP-6 and GHRP-2 can raise prolactin at higher doses

There are now three GLP-1RA drugs approved in multiple countries [see Table 1] for chronic weight management, all of which are administered as injections: Wegovy (active substance semaglutide) and Saxenda (active substance liraglutide) from Novo Nordisk, and Mounjaro/Zepbound 1 (active substance tirzepatide) from Eli Lilly the latter being the first dual receptor agonist 2 drug approved

So far, the long-term change of weight after discontinuation of AOMs is still lacking of systematic evaluation

The addition of GIP enhances insulin sensitivity and may provide more significant glucose and weight management benefits